Stage IV Renal Cell Cancer Clinical Trial
Official title:
A Phase II Study of OSI-774 (NSC-718781) in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer
This phase II trial is studying how well erlotinib works in treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
PRIMARY OBJECTIVES:
I. To assess response (confirmed complete and partial response) of patients with locally
advanced or metastatic papillary histology renal cell cancer treated with OSI-774.
II. To assess the overall survival and 6-month probability of treatment failure of this
group of patients.
III. To evaluate the qualitative and quantitative toxicities of this regimen. IV. To
investigate in a preliminary manner the association of tumor response with tumor expression
of epidermal growth factor receptor and status of von Hippel Lindau gene mutation.
OUTLINE:
Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 5-20
months.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01740154 -
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
|
N/A | |
Completed |
NCT00101114 -
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01243359 -
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT00278395 -
Vorinostat in Treating Patients With Kidney Cancer
|
Phase 2 | |
Terminated |
NCT00098618 -
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00006486 -
Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01684397 -
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Completed |
NCT01265368 -
A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)
|
Phase 1/Phase 2 | |
Completed |
NCT00408902 -
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00005799 -
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
|
N/A | |
Completed |
NCT00019539 -
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
|
Phase 2 | |
Completed |
NCT02899078 -
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02944617 -
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
|
N/A | |
Completed |
NCT01727089 -
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00499135 -
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01943188 -
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
|
Phase 1 |